Medical Director, Inflammatory Bowel Disease Center
The Ohio State University Wexner Medical Center
Hilliard, OH, United States
Anita Afzali, MD, MPH, FACG, is a Professor of Clinical Medicine and a Gastroenterologist that specializes in Inflammatory Bowel Disease (IBD) at The Ohio State University Wexner Medical Center. She is the Medical Director of the OSU Inflammatory Bowel Disease Center. She holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. She is currently working on another Master's in Health Care Management for physician excecutive leadership and business administration from Harvard. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. Her research interests include clinical outcomes and association of bowel and joint disease, influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials including nearly 30 investigational drug trials as site principal investigator, nutrition studies, and diagnostic biomarker research in IBD. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees. She is an Associate Editor for the American Journal of Gastroenterology, Vice Chair of the ACG Educational Affairs Committee, Co-Chair of the World Gastroenterology Organization (WGO) e-WGN, Vice Chair of the WGO Publications committee.
AbbVie (Individual(s) Involved: Self): Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau; Arena Pharmaceuticals (Individual(s) Involved: Self): Consultant; Bristol Myers Squibb (Individual(s) Involved: Self): Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau; DiaSorin (Individual(s) Involved: Self): Consultant; IBD Horizons (Individual(s) Involved: Self): Advisory Committee/Board Member, Consultant, Grant/Research Support; Janssen (Individual(s) Involved: Self): Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau; Lilly (Individual(s) Involved: Self): Consultant, Grant/Research Support; Pfizer (Individual(s) Involved: Self): Consultant, Grant/Research Support, Speaker's Bureau; Takeda (Individual(s) Involved: Self): Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau; TLL Pharma (Individual(s) Involved: Self): Advisory Committee/Board Member, Consultant